<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392546</url>
  </required_header>
  <id_info>
    <org_study_id>000185</org_study_id>
    <nct_id>NCT02392546</nct_id>
  </id_info>
  <brief_title>Elobixibat Colonic Motor Function Study</brief_title>
  <official_title>A Single Center, Placebo-controlled Trial to Evaluate the Effects of Elobixibat in Colonic Motor Functions in Patients With Chronic Idiopathic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial of 36 otherwise healthy patients with chronic idiopathic
      constipation. The purpose of the study is to compare the effects of daily single-dose oral
      elobixibat and placebo for 7 days on colonic motor effects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business reasons
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of postprandial High Amplitude Propagated Contractions (HAPCs)</measure>
    <time_frame>At Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Colonic Tone</measure>
    <time_frame>At Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial tone relative to fasting</measure>
    <time_frame>At Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting colonic tone</measure>
    <time_frame>At Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic sensation threshold for first sensation</measure>
    <time_frame>At Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic sensation threshold for gas</measure>
    <time_frame>At Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic sensation threshold for pain</measure>
    <time_frame>At Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 48h fecal bile acid excretion</measure>
    <time_frame>At Day 4-6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Idiopathic Constipation</condition>
  <arm_group>
    <arm_group_label>Elobixibat 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>elobixibat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elobixibat 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>elobixibat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elobixibat 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>elobixibat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elobixibat</intervention_name>
    <arm_group_label>Elobixibat 10 mg</arm_group_label>
    <arm_group_label>Elobixibat 15 mg</arm_group_label>
    <arm_group_label>Elobixibat 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18-65 years of age

          -  Body Mass Index of 18-40 kg/m2

          -  Diagnosis of constipation for 12 or more weeks with symptom onset at least 6 months
             prior to the diagnosis and insufficient criteria to fulfill a diagnosis of irritable
             bowel syndrome (IBS), as defined by the Rome III criteria for Functional Constipation

          -  Stable concomitant medications defined as no changes in regimen for at least 2 weeks
             prior to the trial period

        Exclusion Criteria:

          -  Structural or metabolic diseases/conditions that affect the gastrointestinal system,
             or functional gastrointestinal (GI) disorders.

          -  Use of drugs or agents within the past 2 weeks that alter GI transit including
             laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin,
             narcotics, anticholinergics, tricyclic antidepressants, selective serotonin reuptake
             inhibitor and newer antidepressants

          -  Use of drugs or agents within the past 2 weeks that may add drowsiness and central
             nervous system (CNS) depression such as barbiturates, benzodiazepines, ethanol,
             lithium, opioids, buspirone, antihistamines, muscle relaxants, and other CNS
             depressants

          -  The patient has a history of bariatric surgery for treatment of obesity; surgery to
             remove a segment of the GI tract; or surgery of the abdomen, pelvic or retroperitoneal
             area during the 6 months prior to Screening; or appendectomy or cholecystectomy 3
             months prior to screening; or other major surgery 1 month prior to Screening

          -  Clinical evidence (including physical exam) of clinically significant cardiovascular,
             respiratory, renal, hepatic, gastrointestinal, hematological, neurological,
             psychiatric, or other disease that interfere with the objectives of the trial. Any
             candidate participants with such disorder mentioned will be referred to their general
             physician

          -  The Hospital Anxiety and Depression Scale (HADS) will be used to exclude patients with
             significant affective disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

